US IPO Weekly Winners & Losers
I'm LongbridgeAI, I can summarize articles.The Renaissance IPO Index rebounded 8.6%, outperforming the S&P 500's 3.6% gain, driven by biotech and AI sectors. Braveheart Bio surged 65.6% on strong data, while SpaceX rose 23% post-lock-up. Biotech and AI infrastructure remain key themes for fall, with potential mega-IPOs from Anthropic or OpenAI anticipated. Londian Wason New Energy Tech plans a $75 million offering, and Robinhood Ventures Fund II aims to raise $200 million.
New stocks won the week: The Renaissance IPO Index rebounded +8.6%.
After three straight down weeks, the IPO market crushed the S&P 500, which rose +3.6%. Our IPO Index is back above +20% for the year, now that July’s AI sell-off has reversed.
Biotech IPOs continued their winning streak, with four new listings from clinical-stage drug developers. Braveheart Bio (Nasdaq: BRVE), which targets cardiovascular disease, completed the week's largest IPO and popped +65.6%, boasting strong Phase 2 data and a cornerstone investment from Fidelity. The week's other biotech deals (ATTO, LTGO, BLSM) were more modest, but none finished negative.
SpaceX had the most talked-about IPO lock-up release of all time, after its first public earnings announcement. The stock finished the week up +23%, nearly back to the offer price. Improved AI sentiment helped, but as Avery and Matt mentioned on the previous W&L podcast, lower-than-expected insider selling after a lock-up release can be a buy signal.
The Big Picture: Biotech and AI infrastructure will continue to be major themes in the fall. And if SpaceX continues this rally, that raises the odds of a mega-IPO from Anthropic or OpenAI.
For now, it’s “last call” for the 2026 summer IPO market. A typical IPO calendar would give companies one more week to launch their offerings before the annual August lull.
The Week Ahead: China-based Londian Wason New Energy Tech (NYSE: FOIL) is raising $75 million in a deal led by Cantor. The company produces copper foils used in batteries. We don't count closed-end funds in our IPO stats, but Robinhood Ventures Fund II (NYSE: RVII) aims to raise $200 million, with a portfolio of dozens of smaller private tech companies.
Index Movers: The IPO Index’s winner and loser this week were both AI-powered diagnostics companies. Downtrodden Caris Life Sciences (CAI) jumped +45.1% on a beat-and-raise quarter. BillionToOne (BLLN) slid -32.6% after the much-hyped company put up a decent quarter but merely reiterated 2026 guidance.
The Renaissance IPO Index returned 8.6% last week vs. 3.6% for the S&P 500.